Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial
UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.
Previous Post
Impact of EDS on Patients’ Quality of Life and Identifying Sleepiness in OSA
Next Post
EHR or PM: How Having Both Can Help Your Practice’s Bottom Line
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago